Press Room http://www.news.sanofi.us/ MediaRoom Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients http://www.news.sanofi.us/2017-05-22-Sanofi-and-Regeneron-Announce-FDA-Approval-of-Kevzara-R-sarilumab-for-the-Treatment-of-Moderately-to-Severely-Active-Rheumatoid-Arthritis-in-Adult-Patients - Kevzara is now available to U.S. patients - Mon, 22 May 2017 17:47:00 -0400 http://www.news.sanofi.us/2017-05-22-Sanofi-and-Regeneron-Announce-FDA-Approval-of-Kevzara-R-sarilumab-for-the-Treatment-of-Moderately-to-Severely-Active-Rheumatoid-Arthritis-in-Adult-Patients Allegra® Allergy Gears Up for Bike to Work Day Across the U.S. http://www.news.sanofi.us/2017-05-11-Allegra-R-Allergy-Gears-Up-for-Bike-to-Work-Day-Across-the-U-S -- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season -- Thu, 11 May 2017 08:30:00 -0400 http://www.news.sanofi.us/2017-05-11-Allegra-R-Allergy-Gears-Up-for-Bike-to-Work-Day-Across-the-U-S Sanofi Pricing Principles for the U.S. http://www.news.sanofi.us/Sanofi-Pricing-Principles-for-the-U-S Op-Ed by Olivier Brandicourt Tue, 09 May 2017 07:00:00 -0400 http://www.news.sanofi.us/Sanofi-Pricing-Principles-for-the-U-S Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment http://www.news.sanofi.us/2017-05-02-Survey-Results-Show-Eighty-Percent-of-Rheumatoid-Arthritis-Patients-Report-Life-Altering-Pain-Daily-or-Multiple-Times-a-Week-Despite-Treatment - New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA - Tue, 02 May 2017 08:30:00 -0400 http://www.news.sanofi.us/2017-05-02-Survey-Results-Show-Eighty-Percent-of-Rheumatoid-Arthritis-Patients-Report-Life-Altering-Pain-Daily-or-Multiple-Times-a-Week-Despite-Treatment Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Kevzara-R-sarilumab-Biologics-License-Application-Resubmission-Accepted-for-Review-by-US-FDA - New action date for Kevzara U.S. BLA is May 22, 2017 - Fri, 28 Apr 2017 08:28:00 -0400 http://www.news.sanofi.us/Sanofi-and-Regeneron-Announce-Kevzara-R-sarilumab-Biologics-License-Application-Resubmission-Accepted-for-Review-by-US-FDA